$AZN $MRK Lynparza significantly delayed disease progression as 1stline maintenance treatment in germline BRCAmutated metastatic pancreatic cancer httpswww.astrazeneca.commediacentrepressreleases2019lynparzasignificantlydelayeddiseaseprogre

$AZN $MRK Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progre

03:12 EST 26 Feb 2019 | Odi Bruckman

$AZN $MRK Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019.html …

More From BioPortfolio on "$AZN $MRK Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progre"